Insulin glulisine

Insulin glulisine is a rapid-acting insulin analogue that differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid.[1] It was developed by Sanofi-Aventis and is sold under the trade name Apidra.[2] When injected subcutaneously, it appears in the blood earlier than human insulin.[3] When used as a meal time insulin, the dose is to be administered within 15 minutes before or 20 minutes after starting a meal.[4] Intravenous injections may also be used for extreme hyperglycemia, but must be performed under the supervision of a medical professional.[5]

Insulin glulisine
Clinical data
Trade namesApidra
AHFS/Drugs.comMonograph
MedlinePlusa607033
License data
Pregnancy
category
  • US: C (Risk not ruled out)
    Routes of
    administration    		Subcutaneous
    ATC code
    Legal status
    Legal status
    Identifiers
    CAS Number
    DrugBank
    ChemSpider
    • none
    UNII
    KEGG
    Chemical and physical data
    FormulaC258H384N64O78S6
    Molar mass5822.64 g·mol−1
     NY (what is this?)  (verify)

    References
    1. "Apidra (insulin glulisine) injection, solution". DailyMed.
    2. Jasek W, ed. (2007). Austria-Codex (in German) (2007/2008 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 978-3-85200-181-4.
    3. Garnock-Jones KP, Plosker GL (May 2009). "Insulin glulisine: a review of its use in the management of diabetes mellitus". Drugs. 69 (8): 1035–57. doi:10.2165/00003495-200969080-00006. PMID 19496630.
    4. "Insulin Glulisine". Drugs.com.
    5. "Sanofi Prescription Products" (PDF). Sanofi. Retrieved 21 April 2012.
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.